In Chemotherapy for Lung Cancer, Sometimes Less is More

Restricted access

Eric Roeland, MD, is from the UC San Diego Moores Cancer Center in La Jolla, California.

Charles Loprinzi, MD, is from the Mayo Clinic in Rochester, Minnesota.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

Timothy J. Moynihan, MD, is from the Mayo Clinic in Rochester, Minnesota.

Thomas J. Smith, MD, is from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.

Jennifer Temel, MD, is from Massachusetts General Hospital, Boston, Massachusetts.

This work was supported by the following United State National Institutes of Health Grant: CA124477 (PI Charles Loprinzi).

  • 1.

    Massarelli E, Andre F, Liu D. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:5561.

    • Search Google Scholar
    • Export Citation
  • 2.

    Shanafelt TD, Loprinzi C, Marks R. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004;22:19661974.

    • Search Google Scholar
    • Export Citation
  • 3.

    Langer C, Li S, Schiller J. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group Performance Status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007;25:418423.

    • Search Google Scholar
    • Export Citation
  • 4.

    Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13:10871093.

    • Search Google Scholar
    • Export Citation
  • 5.

    Gridelli C. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004;15:419426.

    • Search Google Scholar
    • Export Citation
  • 6.

    Azzoli CG, Baker S Jr, Temin S. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:62516266.

    • Search Google Scholar
    • Export Citation
  • 7.

    Ettinger DS, Akerley W, Bepler G. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740801.

  • 8.

    Riely GJ, Chaft JE, Ladanyi M. Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Canc Netw 2011;9:13281330.

  • 9.

    Earle CC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2003;22:315321.

  • 10.

    Ho TH, Barbera L, Saskin R. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 2011;29:15871591.

    • Search Google Scholar
    • Export Citation
  • 11.

    Murillo JR, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 2006;11:10951099.

    • Search Google Scholar
    • Export Citation
  • 12.

    Emanuel EJ, Young-Xu Y, Levinsky NG. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 2003;138:639643.

  • 13.

    Connor SR, Pyenson B, Fitch K. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007;33:238246.

    • Search Google Scholar
    • Export Citation
  • 14.

    Saito A, Landrum MB, Neville B. The effects on survival of continuing chemotherapy to near death. BMC Palliat Care 2011;10:14.

  • 15.

    Temel JS, Greer JA, Muzikansky A. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733742.

    • Search Google Scholar
    • Export Citation
  • 16.

    Colby WH, Dahlin C, Lantos J. The National Consensus Project for Quality Palliative Care Clinical Practice Guidelines Domain 8: ethical and legal aspects of care. HEC Forum 2010;22:117131.

    • Search Google Scholar
    • Export Citation
  • 17.

    Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:25422550.

    • Search Google Scholar
    • Export Citation
  • 18.

    Ciuleanu T, Brodowicz T, Zielinski C. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:14321440.

    • Search Google Scholar
    • Export Citation
  • 19.

    Bakitas M, Lyons KD, Hegel MT. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009;302:741749.

    • Search Google Scholar
    • Export Citation
  • 20.

    Connor SR, Pyenson B, Fitch K. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007;33:238246.

    • Search Google Scholar
    • Export Citation
  • 21.

    Greer JA, McMahon PM, Tramontano A. Effect of early palliative care on health care costs in patients with metastatic NSCLC [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 6004.

    • Search Google Scholar
    • Export Citation
  • 22.

    Asahina H, Sekine I, Horinouchi H. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2012;13:3943.

    • Search Google Scholar
    • Export Citation
  • 23.

    Massarelli E, Andre F, Liu DD. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:5561.

    • Search Google Scholar
    • Export Citation
  • 24.

    Shanafelt TD, Loprinzi C, Marks R. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004;22:19661974.

    • Search Google Scholar
    • Export Citation
  • 25.

    Saito AM, Landrum MB, Neville BA. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care 2011;10:14.

  • 26.

    Saito AM, Landrum MB, Neville BA. Hospice care and survival among elderly patients with lung cancer. J Palliat Med 2011;14:929939.

  • 27.

    Nelson JE, Gay EB, Berman AR. Patients rate physician communication about lung cancer. Cancer 2011;117:52125220.

  • 28.

    Huskamp HA, Keating NL, Malin JL. Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med 2009;169:954962.

    • Search Google Scholar
    • Export Citation
  • 29.

    Christakis NA, Lamont EB, Smith JL. Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ 2000;320:469472.

    • Search Google Scholar
    • Export Citation
  • 30.

    Steensma D, Loprinzi C: The art and science of prognosis in patients with advanced cancer. Eur J Canc 2000;36:20252027.

  • 31.

    Panagopoulou E, Panagopoulou E, Panagopoulou E. Concealment of information in clinical practice: is lying less stressful than telling the truth? J Clin Oncol 2008;26:11751177.

    • Search Google Scholar
    • Export Citation
  • 32.

    Keating NL, Landrum MB, Rogers SO Jr. Physician factors associated with discussions about end-of-life care. Cancer 2010;116:9981006.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 61 39 0
PDF Downloads 18 15 0
EPUB Downloads 0 0 0